Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

BACKGROUND: Patients with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. METHODS: The efficacy of inotuzumab ozogamicin (InO), a humanized anti‐CD22 monoclonal antibody conjugated to the cytotox...

Full description

Saved in:
Bibliographic Details
Published in:Cancer
Main Authors: Stock, Wendy, Martinelli, Giovanni, Stelljes, Matthias, DeAngelo, Daniel J., Gökbuget, Nicola, Advani, Anjali S., O’Brien, Susan, Liedtke, Michaela, Merchant, Akil A., Cassaday, Ryan D., Wang, Tao, Zhang, Hui, Vandendries, Erik, Jabbour, Elias, Marks, David I., Kantarjian, Hagop M.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983935/
https://ncbi.nlm.nih.gov/pubmed/33231879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33321
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items